Answers are grounded in this paper and cite their sources.
Case report highlights isolated thrombocytopenia linked to ticagrelor in a patient with acute coronary syndrome.
Ticagrelor is an oral antiplatelet drug. The most common ticagrelor side effects include bleeding, dyspnea, bradycardia and in rare cases, microangiopathic hemolytic anemia. Isolated thrombocytopenia followed by a single-bolus dosage of ticagrelor is extremely uncommon. We encountered a 68-year-old male who had experienced rapid onset of chest pain and sweating for a day. The initial cardiac assessment suggested acute coronary syndrome and other laboratory tests, including a hemogram, were normal. The patient developed severe thrombocytopenia after receiving a loading dose of ticagrelor, despite the fact that no other thrombocytopenia-causing medicines were given to him. After discontinuing ticagrelor, the patient’s platelet count gradually recovered with no need for additional transfusions or unnecessary investigations.
No takes yet. Share an insight, caveat, or question.
Poddar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: